Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
95 results about "Neisseria" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neisseria is a large genus of bacteria that colonize the mucosal surfaces of many animals. Of the 11 species that colonize humans, only two are pathogens, N. meningitidis and N. gonorrhoeae. Most gonococcal infections are asymptomatic and self-resolving, and epidemic strains of the meningococcus may be carried in >95% of a population where systemic disease occurs at <1% prevalence.
Immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:WYETH HOLDINGS LLC
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:WYETH HOLDINGS LLC
Gna1870-Based Vesicle Vaccines for Broad Spectrum Protection Against Diseases Caused by Neisseria Meningitidis
ActiveUS20080248065A1Broad protectionDecrease of emergenceAntibacterial agentsBacterial antigen ingredientsBacteroidesDisease
Owner:CHILDREN S HOSPITAL &RES CENT AT OAKLAN
Poly saccharide-protein combination vaccine
InactiveCN1425465AImproving immunogenicityReduce the number of vaccinationsViral antigen ingredientsKetone active ingredientsMedicineNeisseria
Group A and Group C epidemuic cerebrospinal meningitis Neisseria capsular polysaccharide and type-B influenza Hemophilus polysaccharide are combined onto effective protein carrier chemically via covalent bond, so that combined polysacchairde-protein vaccine for immunologically inocualting human body is prepared to prevent infection caused by Group A and Group C epidemic cerebrospinal meningitis neisseria and type-B influenza Hemophilus.
Owner:BEIJING LUZHU BIOTECH +1
Immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:WYETH LLC
Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
InactiveUS20040185478A1Reduce usageDetermine rapidly the bacterial resistance to antibioticsMicrobiological testing/measurementFermentationBacteroidesNeisseria meningitidis
DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:GENEOHM SCI CANADA
Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
InactiveUS20060263810A1Reduce usageDetermine rapidly the bacterial resistance to antibioticsSugar derivativesMicrobiological testing/measurementNeisseria meningitidisListeria monocytogenes
Owner:GENEOHM SCI CANADA
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
InactiveUS20070082007A1Avoid infectionInhibition of colonizationAntibacterial agentsNervous disorderDiseaseSalmonella serotype typhi
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:ZLOTNICK GARY W +5
Bacterial hemoglobin receptor genes
InactiveUS7026157B1Inhibit and facilitate and modulate biochemical activityAntibacterial agentsSugar derivativesBacteroidesADAMTS Proteins
The present invention relates to novel bacterial hemoglobin receptor proteins and genes that encode such proteins. The invention is directed toward the isolation, characterization, diagnostic and therapeutic use of bacterial hemoglobin receptor proteins, nucleic acid encoding such proteins, recombinant expression constructs comprising such nucleic acids and cells transformed therewith, and antibodies and epitopes of such hemoglobin receptor proteins. The invention relates particularly to hemoglobin receptor proteins and genes encoding such proteins from Neisseria species, especially N. meningitidis and serotypes thereof, and N. gonorrhoeae. Methods for the diagnostic and therapeutic use of the proteins, epitopes, antibodies and nucleic acids of the invention are also provided, including the use of the proteins, epitopes, antibodies and nucleic acids of the invention for the production of vaccines effectinve in providing immunization of a human against infection by pathogenic bacteria of Neisseria species.
Owner:OREGON HEALTH & SCI UNIV
Species-specific, genus-specific and universal DNA probes and amplification primers to rapidly detect and identify common bacterial and fungal pathogens and associated antibiotic resistance genes from clinical specimens for diagnosis in microbiology laboratories
InactiveUS20030049636A1Low costRapid positioningMicrobiological testing/measurementFermentationBacteroidesNeisseria meningitidis
DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample DNA from (i) any bacterium, (ii) the species Streptococcus agalactiae, Staphylococcus saprophyticus, Enterococcus faecium, Neisseria meningitidis, Listeria monocytogenes and Candida albicans, and (iii) any species of the genera Streptococcus, Staphylococcus, Enterococcus, Neisseria and Candida are disclosed. DNA-based methods employing amplification primers or probes for detecting, identifying, and quantifying in a test sample antibiotic resistance genes selected from the group consisting of blatem, blarob, blashv, blaoxa, blaZ, aadB, aacC1, aacC2, aacC3, aacA4, aac6'-lla, ermA, ermB, ermC, mecA, vanA, vanB, vanC, satA, aac(6')-aph(2''), aad(6'), vat, vga, msrA, sul and int are also disclosed. The above microbial species, genera and resistance genes are all clinically relevant and commonly encountered in a variety of clinical specimens. These DNA-based assays are rapid, accurate and can be used in clinical microbiology laboratories for routine diagnosis. These novel diagnostic tools should be useful to improve the speed and accuracy of diagnosis of microbial infections, thereby allowing more effective treatments. Diagnostic kits for (i) the universal detection and quantification of bacteria, and / or (ii) the detection, identification and quantification of the above-mentioned bacterial and fungal species and / or genera, and / or (iii) the detection, identification and quantification of the above-mentioned antibiotic resistance genes are also claimed.
Owner:BERGERON MICHEL G +3
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
InactiveUS20110076299A1Antibacterial agentsOrganic active ingredientsDiseaseSalmonella serotype typhi
Owner:WYETH HOLDINGS LLC
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:WYETH LLC
Conserved Neisserial antigens
InactiveUS7368261B1Easy to useReduce complexityAntibacterial agentsPeptide/protein ingredientsAntigenSalmonella serotype typhi
To ensure maximum cross-strain recognition and reactivity, regions of proteins that are conserved between different Neisserial species, serogroups and strains can be used. The invention provides proteins which comprise stretches of amino acid sequence that are shared across the majority of Neisseria, particularly N. meningitidis and N. gonorrhoeae.
Owner:NOVARTIS AG
Probiotic Oral Health Promoting Product
The present invention discloses an oral composition comprising a combination of probiotic bacteria selected from the group comprising Streptococcus, Eubacterium, Neisseria, Veillonella and pH-rising and / or buffering components, which re-establishes an oral microflora associated with good oral health in subjects with a disturbed oral microflora. The invention also discloses the use of the oral composition in combination with other oral health promoting products to help subjects suffering from disorders such as oral dryness, caries, halitosis, inflamed oral mucous membranes or oral fungal infections to restore good oral health.
Owner:WIKSTROM MAUDE +1
Neisseria mutants, lipooligosaccharides and immunogenic compositions
Provided herein are mutant strains of Neisseria meningitidis which produce Kdo-free lipid A as well as the Kdo-free lipid A molecules and immunogenic compositions containing such Kdo-free lipid A molecules from a Neisseria strain containing a genetically stable mutation which inactivates a gene selected from the group consisting of genes encoding arabinose-5-phosphate isomerase, CMP-Kdo synthetase and CMP-Kdo transferase. N. meningitidis NMB206 is a specifically exemplified strain which harbors a stable insertion mutation in the gene (ApsF) encoding A5P isomerase; strain NMB-249 is a specifically exemplified strain with a stable insertion mutation in the gene (kdtA) encoding CMP-Kdo synthetase, and strain NMB259 is specifically exemplified strain with a stable insertion mutation in the gene (kdsB) encoding CMP-Kdo transferase. Also provided by the present invention are methods for the production of Lipid A flee of 3-keto-3-deoxyoctanoic acid using these genetically stable N. meningitidis mutants. Also describes is pYT250, a plasmid functional in neisseriae and in enterics such as Escherichia coli.
Owner:EMORY UNIVERSITY
Application of Harmine derivative to preparation of antibacterial medicine
The invention discloses application of a Harmine derivative to preparation of antibacterial medicines. The bacteria is selected from Acinetobacter, Bacillus, Campylobacter, Chlamydia, Chlamydia trachomatis, Clostridium, Citrobacter, Escherichia, enterohemorrhagic escherichia coli, enteric bacteria, Enterococcus, Francisella, Haemophilus, helicobacter, Klebsiella Bacillus, Lester monocytogenes, Moraxella, Mycobacterium, Neisseria, proteus, Pseudomonas, Salmonella, shewanella oneidensis, Shigella, Stenotrophomonas, Staphylococcus, Streptococcus and Yersinia.
Owner:XINJIANG HUASHIDAN PHARMA RES
Neisseria genomic sequences and methods of their use
InactiveUS20050191316A1Easy to insertEfficient HarvestingAntibacterial agentsBacteriaSAA proteinNucleotide
The invention provides methods of obtaining immunogenic proteins from genomic sequences including Neisseria, including the amino acid sequences and the corresponding nucleotide sequences, as well as the genomic sequence of Neisseria meningitidis B. The proteins so obtained are useful antigens for vaccines, immunogenic compositions, and / or diagnostics.
Owner:GLAXOSMITHKLINE BIOLOGICALS SA
Epidemic meningitis polyose-protein binding vaccine
A polyose-protein vaccine for epidemic cerebrospinal meningitis is prepared through chemically binding the two Neisseria capsular polyoses of cluster-A and-C epidemic cerebrospinal meningitis with protein carrier by covalent bonds.
Owner:BEIJING LUZHU BIOTECH
Neisseria meningitidis capsular polysacchride conjugates
InactiveUS6080589AEnhance host immune responseImproving immunogenicityBiocideOrganic active ingredientsChemical reactionSialic acid
Capsular polysaccharides containing multiple sialic acid residues, particularly the Group B polysaccharide of Neisseria meningitidis, are modified by chemical reaction to randomly introduce pendant reactive residues of heterobifunctional linker molecules to the polysaccharide backbone. The capsular polysaccharide is deacetylated and the heterobifunctional linker molecule is reacted with the deacetylated material and any residual amino groups are blocked by reaction with alkyl acid anhydride. The introduction of the linker molecules to the polysaccharide chain between the termini enables the polysaccharide to be linked to a carrier molecule, such as a protein, to enhance the immunogenicity of the polysaccharide. The conjugate molecule may be formulated as an immunogenic composition for raising antibodies in a host to the polysaccharide.
Owner:CONNAUGHT LAB
A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process
InactiveCN105031634AKeep healthyAvoid pollutionAntibacterial agentsCarrier-bound antigen/hapten ingredientsConjugate vaccineVaccine manufacturing
The invention discloses an A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process. The problem that highly-toxic chemical reagents, such as cyanogen bromide, are used in the vaccine manufacturing process in the prior art and accordingly are harmful to protection of human health and environment is solved. The A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process comprises the following steps of 1 cultivating Neisseria meningitidis, 2 utilizing the cultivated Neisseria meningitidis to extract crude polysaccharide, 3 purifying the crude polysaccharide to prepare refined Neisseria meningitidis polysaccharide and 4 activating and deriving the refined polysaccharide. The A-group C-group Neisseria meningitidis polysaccharide conjugate vaccine activating process has the advantages that the extraction rate of the polysaccharide from a capsule is higher, the precipitation rate of the polysaccharide is higher, the recovery rate and purity of the refined polysaccharide are high, the derivation effect is better and the like.
Owner:CHENGDU OLYMVAX BIOPHARM
Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
InactiveUS20110182942A1High expressionAntibacterial agentsBacterial antigen ingredientsDiseaseMeningococcal carriage
The present technology provides vaccine compositions comprising native outer membrane vesicles (NOMVs) from at least one genetically modified strain of Neisseria which provides protective immunity to meningococcal disease, more preferably subtype B meningococcal disease. The present technology further provides methods of immunizing an animal or human against meningococcal disease comprising administering the vaccine composition of the present invention.
Owner:US ARMY MEDICAL RES MATERIEL COMMAND USAMRMC
Method of treating subject infected with Neisseria gonorrhea
InactiveUS7094809B2Reducing cytopathic effectAvoid spreadingAntibacterial agentsBiocideVaricella-zoster virus infectionCytomegalovirus infections
The present invention provides a method of inhibiting the formation of infectious herpes virus particles, particularly infectious herpes simplex virus (HSV) particles, in a host cell. The method involves administering an effective amount of a hydroxylated tolan, particularly a polyhydroxylated tolan, to a herpes virus infected host cell. The present invention also provides a method of treating a herpes virus infection, particularly an HSV infection. The method comprises administering a topical composition comprising a therapeutically effective amount of a hydroxylated tolan to a herpes virus-infected site. The present invention also relates to a topical composition for treating a herpes virus infection selected from the group consisting of an HSV infection, a cytomegalovirus infection, and a varicella zoster virus infection. The present invention also provides a method of treating a subject infected with Neisseria gonorrhea.
Owner:NORTHEASTERN OHIO UNIVERSITIES COLLEGE OF MEDICINE +1
Chlamydia trachomatis specific oligonucleotide sequences
The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the selective and specific detection of Chlamydia trachomatis in biological samples. The invention also provides oligonucleotide primer sets and primer / probe sets in the form of kits for the detection and diagnosis of chlamydial infection. The inventive oligonucleotide primers and probes can also be used in combination with other specific oligonucleotide primers and probes for the simultaneous detection ofChlamydia trachomatis and other target organisms, such as Neisseria gonorrhea.
Owner:SIEMENS HEALTHCARE DIAGNOSTICS INC
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:WYETH LLC
B-group epidemic neisseria meningitidis recombinant protein vaccine and preparing method thereof
ActiveCN104888209AGood antigenicityImproving immunogenicityAntibacterial agentsAntibody medical ingredientsIntraperitoneal routeProtein detection
The invention provides a B-group epidemic neisseria meningitidis recombinant protein vaccine and a preparing method thereof, and belongs to the field of biological products. The vaccine contains three mutant recombinant proteins of a human H factor binding protein. The invention further provides a preparing method of the B-group epidemic neisseria meningitidis recombinant protein vaccine. The method includes the steps of human H factor binding protein V1, V2 and V3 recombinant expression carrier construction, expression strain screening and identification, fermental cultivation, recombinant protein antigen inducible expression and recombinant protein antigen purification and protein detection; and according to the concentrations of the three antigen components, quantified mixing is carried out, and the B-group epidemic neisseria meningitidis recombinant protein vaccine is prepared in cooperation with an aluminum adjuvant. By means of the B-group epidemic neisseria meningitidis recombinant protein vaccine, intraperitoneal injection is carried out on an immune mice, the mice body can be stimulated to generate a B-group epidemic neisseria resisting peculiar antibody, and the alexin mediated serum sterilization antibody can rise by more than 8 times.
Owner:BEIJING MINHAI BIOTECH
Nucleotides with specificity to internal transcribed spacer(ITS) of neisseria meningitidis and application thereof
ActiveCN102154466APracticalThe preparation method is simple and easyMicrobiological testing/measurementMicroorganism based processesSocial benefitsNucleotide
The invention relates to nucleotides SEQ ID NO: 1 to SEQ ID NO: 3 with specificity to the 16S rRNA-23S rRNA internal transcribed spacer (ITS) of neisseria meningitidis and application thereof, and provides a fluorescent quantitative PCR(polymerase chain reaction) detection kit and a detection method by using oligonucleotide as a primer and a probe. The fluorescent quantitative PCR detection kit has the advantages of simple operation, quick result, good specificity and high sensitivity when used for detecting the neisseria meningitidis in a human body and environment, can be used in fields such as supervision and detection of foods and clinical samples, detection of pathogenic bacteria of foods, bacteriological classification and epidemiological study and has significant social benefit andgreat economic benefit.
Owner:TIANJIN BIOCHIP TECH CO LTD
Method for quickly detecting gonorrhea Neisseria by utilizing loop-mediated isothermal amplification technology
InactiveCN101831488AAvoid painMicrobiological testing/measurementMicroorganism based processesClinics outpatientsFluorescence
The invention belongs to biomedical diagnosis, and discloses a method for detecting gonorrhea Neisseria by utilizing a loop-mediated isothermal amplification technology and a sequence of a primer used by the method. By combining the loop-mediated isothermal amplification technology with the fluorochrome development, the method can realize quick isothermal nucleic acid amplification of the specific DNA sequence of gonorrhea Neisseria and result detection on the premise of not using a PCR amplifier, an electrophoresis apparatus or an ultraviolet gel imaging system. The method is simple to operate, and can be used for detecting the gonorrhea Neisseria in urethral secretions of a clinic outpatient or serves as a method for self-check of patients.
Owner:孙星江
Novel immunogenic compositions for the prevention and treatment of meningococcal disease
InactiveUS20070082006A1Avoid infectionInhibition of colonizationAntibacterial agentsNervous disorderDiseaseSalmonella serotype typhi
The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
Owner:ZLOTNICK GARY W +5
Neisseria meninigitidis polypeptide, nucleic acid sequence and uses thereof
InactiveUS20020018782A1Broad cross-strain protectionIncrease the gapAntibacterial agentsOrganic active ingredientsNucleic acid sequencingNucleotide sequencing
The invention discloses the Neisseria meningitidis NMASP polypeptide, polypeptides derived therefrom (NMASP-derived polypeptides), nucleotide sequences encoding said polypeptides, and antibodies that specifically bind the NMASP polypeptide and / or NMASP-derived polypeptides. Also disclosed are prophylactic or therapeutic compositions, including immunogenic compositions, e.g., vaccines, comprising NMASP polypeptide and / or a NMASP-derived polypeptide. The invention additionally discloses methods of inducing a immune response to Neisseria meningitidis and Neisseria meningitidis NMASP polypeptide and an NMASP-derived polypeptide in animals.
Owner:EMERGENT PROD DEV GAITHERSBURG INC
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com